Evidence map›Paper›PMID 42115750›Full record

ArticleNPJ digital medicine2026

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.

Maximilian Ferle, Jonas Ader, Thomas Wiemers, Nora Grieb, Beatrice Berneck, Adrian Lindenmeyer, Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Hans-Jonas Meyer and 4 more

Erratum issuedAbstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Maximilian Ferle *Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Universität Leipzig, Leipzig, Germany. maximilian.ferle@uni-leipzig.de.
Jonas Ader *Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Universität Leipzig, Leipzig, Germany.
Thomas WiemersInnovation Center Computer Assisted Surgery (ICCAS), University of Leipzig, Leipzig, Germany.
Nora GriebInnovation Center Computer Assisted Surgery (ICCAS), University of Leipzig, Leipzig, Germany.
Beatrice BerneckDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectiology, University Hospital of Leipzig, Leipzig, Germany.
Adrian LindenmeyerCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Universität Leipzig, Leipzig, Germany.
Hartmut GoldschmidtDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Elias K MaiDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Uta BertschDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Hans-Jonas MeyerDepartment of Diagnostic and Interventional Radiology, University Hospital Leipzig, Leipzig, Germany.
Thomas NeumuthCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Universität Leipzig, Leipzig, Germany.
Markus KreuzDepartment of Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Kristin ReicheCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Universität Leipzig, Leipzig, Germany.
Maximilian MerzDepartment of Hematology, Hemostaseology, Cellular Therapy and Infectiology, University Hospital of Leipzig, Leipzig, Germany.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
European Union CERTAINTYGerman Research Foundation SPP µboneInternational Myeloma Society IMS Research Grant 2023NCI NIH HHS P30 CA008748Sächsisches Staatsministerium für Wissenschaft, Kultur und Tourismus ScaDS.AI
6 · The paper itself

Abstract

Risk stratification is an important tool in clinical decision-making, yet current approaches often fail to translate sophisticated survival analysis into actionable clinical criteria. We present a novel method for training any neural network architecture on any data modality to identify prognostically distinct patient groups by directly optimizing for survival heterogeneity across patient clusters. We evaluate the method in simulation experiments and demonstrate its utility in practice by applying it to two distinct cancer types: analyzing laboratory parameters from multiple myeloma (MM) patients using the CoMMpass dataset and computed tomography images from non-small cell lung cancer (NSCLC) patients using the Lung1 dataset. Post-hoc explainability analyses uncover clinically meaningful features determining group assignments, which align well with established risk factors in both cases. Our findings in MM were externally validated using the GMMG-MM5 study dataset, while the NSCLC findings were validated with data from our own institution, thus lending strong weight to the method's utility. This pan-cancer, model-agnostic approach enables the discovery of novel prognostic signatures across diverse data types while providing interpretable results that promise to complement treatment personalization and clinical decision-making in oncology and beyond.

Identifiers

PMID42115750
PMCPMC13161318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.